Donepezil Hydrochloride Tablet
Product Images NDC 72162-2136

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 72162-2136). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)

Figure 1. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig1)
A line graph depicting the mean change from baseline in ADAS-cog scores over 30 weeks of drug treatment. It compares Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups, showing the treatment period followed by placebo. The y-axis indicates clinical improvement above baseline and clinical decline below, and the x-axis represents weeks of treatment.*
FDA Label Image

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)

Figure 10. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Adcs-adl-severe Scores. (Donepezil Fig10)
A line graph comparing the cumulative percentage of patients versus ADCS-ADL change from baseline between Donepezil Hydrochloride 10 mg/day and placebo groups. The x-axis shows ADCS-ADL change from baseline, while the y-axis shows the cumulative percentage of patients. The graph displays two lines representing the two groups, illustrating their respective distributions across the measured changes.*
FDA Label Image

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)

Figure 11. Time-course Of The Change From Baseline In Sib Score For Patients Completing 24 Weeks Of Treatment. (Donepezil Fig11)
A line graph depicting the change from baseline in SIB scores over 24 weeks of treatment with Donepezil Hydrochloride at 10 mg/day and 23 mg/day dosages. The vertical axis shows the LS mean SIB change with clinical improvement and decline indicated, and the horizontal axis shows weeks of drug treatment. The 23 mg/day group shows greater improvement compared to the 10 mg/day group.*
FDA Label Image

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)

Figure 12. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Sib Scores. (Donepezil Fig12)
A cumulative percentage of patients graph showing SIB (Severe Impairment Battery) change from baseline. The graph compares Donepezil Hydrochloride at dosages of 23 mg/day and 10 mg/day, plotting percentage of patients on the y-axis against SIB change on the x-axis from positive to negative values.*
FDA Label Image

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)

Figure 13. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig13)
Bar chart comparing the percentage of patients with different CIBIC-plus ratings for Donepezil Hydrochloride at 10 mg/day and 23 mg/day doses. Ratings include markedly improved, moderately improved, minimally improved, no change, minimally worse, moderately worse, and markedly worse, with no change and minimal improvement showing the highest patient percentages.*
FDA Label Image

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)

Figure 2. Cumulative Percentage Of Patients Completing 24 Weeks Of Double-blind Treatment With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 80%, 5 mg/day 85%, And 10 mg/day 68%. (Donepezil Fig2)
A cumulative percentage curve chart showing the change from baseline in ADAS-cog scores for patients treated with placebo, Donepezil Hydrochloride 5 mg, and Donepezil Hydrochloride 10 mg. The graph includes a table summarizing the percentage of patients in each treatment group achieving various changes in ADAS-cog scores at points -7, -4, 0, and 8.*
FDA Label Image

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)

Figure 3. Frequency Distribution Of Cibic-plus Scores At Week 24. (Donepezil Fig3)
Bar chart depicting the percentage of patients with different CIBIC-plus ratings comparing Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo groups. Ratings range from markedly improved to markedly worse, with most patients showing no change or minimal improvement.*
FDA Label Image

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)

Figure 4. Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing The 15-week Study. (Donepezil Fig4)
A line graph showing the ADAS-cog change from baseline mean (±SE) over weeks of drug treatment for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The y-axis represents cognitive change, with clinical improvement indicated upwards and clinical decline downwards. The x-axis tracks treatment duration up to 15 weeks, including a placebo phase.*
FDA Label Image

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)

Figure 5. Cumulative Percentage Of Patients With Specified Changes From Baseline Adas-cog Scores. The Percentages Of Randomized Patients Within Each Treatment Group Who Completed The Study Were: Placebo 93%, 5 mg/day 90%, And 10 mg/day 82%. (Donepezil Fig5)
A cumulative percentage graph showing patient response to Donepezil Hydrochloride and placebo, with three curves representing Donepezil 10 mg/day, 5 mg/day, and placebo. The X-axis shows Change from Baseline, and the Y-axis shows Cumulative Percentage of Patients. The graph includes vertical lines at 4 and 7 point changes and a table summarizing percent changes in ADAS-cog scores at -7, -4, and 0 for placebo, 5 mg/day, and 10 mg/day treatment groups.*
FDA Label Image

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)

Figure 6. Frequency Distribution Of Cibic-plus Scores At Week 12. (Donepezil Fig6)
A bar chart comparing the percentage of patients across different CIBIC-plus Rating categories for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The chart shows categories from Markedly Improved to Markedly Worse along the x-axis, with corresponding patient percentages on the y-axis, illustrating clinical response outcomes.*
FDA Label Image

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)

Figure 7. Time Course Of The Change From Baseline In Sib Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig7)
A line graph showing SIB (Severe Impairment Battery) Change from Baseline over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day and placebo. The y-axis is SIB change from baseline (Mean ± SE) with clinical improvement upward and clinical decline downward. The x-axis shows months of treatment at 0, 3, and 6 months. The Donepezil group shows improvement while placebo shows decline.*
FDA Label Image

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)

Figure 8. Cumulative Percentage Of Patients Completing 6 Months Of Double-blind Treatment With Particular Changes From Baseline In Sib Scores. (Donepezil Fig8)
A cumulative percentage plot comparing Donepezil Hydrochloride 10 mg/day and placebo groups based on SIB (Severe Impairment Battery) change from baseline. The x-axis shows negative SIB change values, and the y-axis represents cumulative percentage of patients, illustrating treatment effects over time.*
FDA Label Image

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)

Figure 9. Time Course Of The Change From Baseline In Adcs-adl-severe Score For Patients Completing 6 Months Of Treatment. (Donepezil Fig9)
A line graph showing the mean change from baseline in ADCS-ADL scores over 6 months of drug treatment. The graph compares Donepezil Hydrochloride 10 mg/day versus placebo, with both groups showing a decline but the Donepezil group having a less steep decline. The vertical axis represents clinical improvement to decline, and the horizontal axis is months of treatment.*
FDA Label Image

Chemical Structure (Donepezil Str)

Chemical Structure (Donepezil Str)
Chemical structure diagram of Donepezil Hydrochloride showing the molecular arrangement of atoms including methoxy groups, piperidine ring, and benzyl group connected to hydrochloride (HCl).*
FDA Label Image

Label (Lbl721622136)

Label (Lbl721622136)
Donepezil Hydrochloride Tablets, USP 5 mg oral tablet label indicating a package of 30 tablets. Labeled by Bryant Ranch Prepack and manufactured by ACI Healthcare Limited. Includes storage instructions, medication guide link, and barcode. NDC 72162-2136.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.